Pacific Biosciences Of California Return on Tangible Equity 2010-2024 | PACB
Current and historical return on tangible equity values for Pacific Biosciences Of California (PACB) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Pacific Biosciences Of California Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2024-09-30 | $-0.39B | $-0.35B | 136.69% |
| 2024-06-30 | $-0.40B | $-0.32B | 166.15% |
| 2024-03-31 | $-0.30B | $-0.26B | 144.70% |
| 2023-12-31 | $-0.31B | $-0.22B | 179.01% |
| 2023-09-30 | $-0.31B | $-0.16B | 170.48% |
| 2023-06-30 | $-0.32B | $-0.18B | 168.56% |
| 2023-03-31 | $-0.32B | $-0.13B | 178.27% |
| 2022-12-31 | $-0.31B | $-0.26B | 185.21% |
| 2022-09-30 | $-0.30B | $-0.19B | 265.48% |
| 2022-06-30 | $-0.20B | $-0.14B | 344.30% |
| 2022-03-31 | $-0.17B | $-0.09B | -435.00% |
| 2021-12-31 | $-0.18B | $-0.03B | -136.62% |
| 2021-09-30 | $-0.04B | $0.02B | -16.14% |
| 2021-06-30 | $-0.08B | $0.26B | -30.71% |
| 2021-03-31 | $-0.06B | $0.28B | -30.03% |
| 2020-12-31 | $0.03B | $0.34B | 20.53% |
| 2020-09-30 | $-0.05B | $0.13B | -64.56% |
| 2020-06-30 | $-0.05B | $0.04B | -98.55% |
| 2020-03-31 | $-0.05B | $0.06B | -87.60% |
| 2019-12-31 | $-0.08B | $0.06B | -121.30% |
| 2019-09-30 | $-0.12B | $0.05B | -136.90% |
| 2019-06-30 | $-0.11B | $0.08B | -106.47% |
| 2019-03-31 | $-0.11B | $0.10B | -102.35% |
| 2018-12-31 | $-0.10B | $0.11B | -94.93% |
| 2018-09-30 | $-0.09B | $0.13B | -91.63% |
| 2018-06-30 | $-0.09B | $0.09B | -96.00% |
| 2018-03-31 | $-0.09B | $0.10B | -91.63% |
| 2017-12-31 | $-0.09B | $0.09B | -100.00% |
| 2017-09-30 | $-0.09B | $0.10B | -98.11% |
| 2017-06-30 | $-0.09B | $0.12B | -93.22% |
| 2017-03-31 | $-0.08B | $0.07B | -86.43% |
| 2016-12-31 | $-0.07B | $0.09B | -76.64% |
| 2016-09-30 | $-0.06B | $0.10B | -59.46% |
| 2016-06-30 | $-0.04B | $0.11B | -46.15% |
| 2016-03-31 | $-0.03B | $0.09B | -50.42% |
| 2015-12-31 | $-0.03B | $0.07B | -65.61% |
| 2015-09-30 | $-0.05B | $0.04B | -115.29% |
| 2015-06-30 | $-0.06B | $0.03B | -131.87% |
| 2015-03-31 | $-0.07B | $0.04B | -129.47% |
| 2014-12-31 | $-0.07B | $0.06B | -108.64% |
| 2014-09-30 | $-0.06B | $0.05B | -99.61% |
| 2014-06-30 | $-0.08B | $0.06B | -104.17% |
| 2014-03-31 | $-0.08B | $0.08B | -92.40% |
| 2013-12-31 | $-0.08B | $0.07B | -86.67% |
| 2013-09-30 | $-0.08B | $0.08B | -83.00% |
| 2013-06-30 | $-0.09B | $0.10B | -77.30% |
| 2013-03-31 | $-0.09B | $0.11B | -71.40% |
| 2012-12-31 | $-0.10B | $0.11B | -68.59% |
| 2012-09-30 | $-0.10B | $0.13B | -60.38% |
| 2012-06-30 | $-0.10B | $0.15B | -56.82% |
| 2012-03-31 | $-0.10B | $0.17B | -50.81% |
| 2011-12-31 | $-0.11B | $0.19B | -49.32% |
| 2011-09-30 | $-0.12B | $0.21B | -50.15% |
| 2011-06-30 | $-0.13B | $0.23B | -62.04% |
| 2011-03-31 | $-0.15B | $0.25B | -91.92% |
| 2010-12-31 | $-0.14B | $0.28B | -146.60% |
| 2010-06-30 | $-0.09B | inf% | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Instruments Manufacturing | $0.471B | $0.201B |
| Pacific Biosciences of California Inc., popularly known as PacBio, develops, manufactures and markets sequencing systems, which help in studying synthesis, composition, structure and regulation of deoxyribonucleic acid, popularly known as DNA. PacBio's products are based on Single Molecule, Real-Time (SMRT) technology. SMRT generates long reads that help in assembling a whole human genome from scratch, without using an existing reference genome as a template. This process is known as de novo assembly. To observe DNA replication process smoothly, PacBio offers the SMRT Cell, Phospholinked nucleotides and The PacBio RS II System. The PacBio RS II System includes the PacBio RS II instrument, consumables and software. PacBio launched its new Sequel system based on SMRT technology. PacBio deferred the gain from the Reverse Termination Fee from Illumina until the date when the associated contingency was resolved. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Thermo Fisher Scientific (TMO) | United States | $194.739B | 23.76 |
| Intuitive Surgical (ISRG) | United States | $191.917B | 100.34 |
| Alcon (ALC) | Switzerland | $42.138B | 28.19 |
| Edwards Lifesciences (EW) | United States | $41.404B | 26.29 |
| IQVIA Holdings (IQV) | United States | $34.726B | 19.13 |
| IDEXX Laboratories (IDXX) | United States | $34.092B | 40.15 |
| DexCom (DXCM) | United States | $29.248B | 44.05 |
| STERIS (STE) | Ireland | $20.926B | 24.09 |
| Waters (WAT) | United States | $20.468B | 30.26 |
| SONOVA HOLDING (SONVY) | Switzerland | $20.297B | 0.00 |
| Hologic (HOLX) | United States | $18.250B | 19.26 |
| Fresenius Medical Care AG KGaA (FMS) | Germany | $12.969B | 13.31 |
| Sysmex ADR (SSMXY) | Japan | $12.688B | 39.79 |
| Globus Medical (GMED) | United States | $11.345B | 28.73 |
| Penumbra (PEN) | United States | $9.100B | 89.14 |
| Teleflex (TFX) | United States | $8.967B | 14.30 |
| Masimo (MASI) | United States | $8.754B | 42.36 |
| Glaukos (GKOS) | United States | $7.951B | 0.00 |
| PROCEPT BioRobotics (PRCT) | United States | $4.883B | 0.00 |
| Integer Holdings (ITGR) | United States | $4.479B | 25.38 |
| Veracyte (VCYT) | United States | $3.034B | 91.05 |
| Inari Medical (NARI) | United States | $2.984B | 0.00 |
| LivaNova (LIVN) | United Kingdom | $2.789B | 16.10 |
| TransMedics (TMDX) | United States | $2.783B | 88.21 |
| Nihon Kohden (NHNKY) | Japan | $2.293B | 17.42 |
| Elekta AB (EKTAY) | Sweden | $2.192B | 17.86 |
| Tandem Diabetes Care (TNDM) | United States | $1.830B | 0.00 |
| RxSight (RXST) | United States | $1.819B | 0.00 |
| Integra LifeSciences Holdings (IART) | United States | $1.766B | 9.23 |
| Alphatec Holdings (ATEC) | United States | $1.357B | 0.00 |
| Artivion (AORT) | United States | $1.129B | 74.81 |
| OPKO Health (OPK) | United States | $1.106B | 0.00 |
| Pulse Biosciences (PLSE) | United States | $1.048B | 0.00 |
| Paragon 28 (FNA) | United States | $0.879B | 0.00 |
| AVANOS MEDICAL, INC (AVNS) | United States | $0.818B | 13.91 |
| ORTHOFIX MEDICAL INC (OFIX) | United States | $0.716B | 0.00 |
| IRadimed (IRMD) | United States | $0.650B | 35.10 |
| OrthoPediatrics (KIDS) | United States | $0.589B | 0.00 |
| AxoGen (AXGN) | United States | $0.561B | 0.00 |
| Mesa Laboratories (MLAB) | United States | $0.542B | 12.77 |
| SiBone (SIBN) | United States | $0.517B | 0.00 |
| Treace Medical Concepts (TMCI) | United States | $0.483B | 0.00 |
| Tactile Systems Technology (TCMD) | United States | $0.378B | 20.48 |
| Semler Scientific (SMLR) | United States | $0.337B | 22.60 |
| CVRx (CVRX) | United States | $0.326B | 0.00 |
| Delcath Systems (DCTH) | United States | $0.317B | 0.00 |
| ClearPoint Neuro (CLPT) | United States | $0.303B | 0.00 |
| NeuroPace (NPCE) | United States | $0.274B | 0.00 |
| AngioDynamics (ANGO) | United States | $0.273B | 0.00 |
| Inogen (INGN) | United States | $0.226B | 0.00 |
| Sight Sciences (SGHT) | United States | $0.191B | 0.00 |
| Accuray (ARAY) | United States | $0.185B | 0.00 |
| Atossa Genetics (ATOS) | United States | $0.161B | 0.00 |
| Alpha Tau Medical (DRTS) | Israel | $0.160B | 0.00 |
| Nevro (NVRO) | United States | $0.159B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.152B | 0.00 |
| Sensus Healthcare (SRTS) | United States | $0.137B | 14.68 |
| Spectral Diagnostics (EDTXF) | Canada | $0.112B | 0.00 |
| EDAP TMS S.A (EDAP) | France | $0.089B | 0.00 |
| WORK Medical Technology Group (WOK) | China | $0.088B | 0.00 |
| LENSAR (LNSR) | United States | $0.087B | 0.00 |
| 908 Devices (MASS) | United States | $0.086B | 0.00 |
| Covalon Technologies (CVALF) | Canada | $0.078B | 0.00 |
| Monogram Orthopaedics (MGRM) | United States | $0.070B | 0.00 |
| InspireMD (NSPR) | Israel | $0.067B | 0.00 |
| EnVVeno Medical (NVNO) | United States | $0.063B | 0.00 |
| Hyperfine (HYPR) | United States | $0.063B | 0.00 |
| Lucid Diagnostics (LUCD) | United States | $0.057B | 0.00 |
| Vicarious Surgical (RBOT) | United States | $0.055B | 0.00 |
| Rapid Micro Biosystems (RPID) | United States | $0.047B | 0.00 |
| Accelerate Diagnostics (AXDX) | United States | $0.044B | 0.00 |
| Envoy Medical (COCH) | United States | $0.040B | 0.00 |
| Adagio Medical Holdings (ADGM) | United States | $0.035B | 0.00 |
| Precision Optics (POCI) | United States | $0.034B | 0.00 |
| Biosig Technologies (BSGM) | United States | $0.033B | 0.00 |
| DarioHealth (DRIO) | United States | $0.027B | 0.00 |
| Neuronetics (STIM) | United States | $0.023B | 0.00 |
| NexGel (NXGL) | United States | $0.022B | 0.00 |
| Spectral AI (MDAI) | United States | $0.021B | 0.00 |
| Inspira Technologies OXY B.H.N (IINN) | Israel | $0.016B | 0.00 |
| Baird Medical Investment Holdings (BDMD) | $0.016B | 0.00 | |
| Microbot Medical (MBOT) | United States | $0.016B | 0.00 |
| Ekso Bionics Holdings (EKSO) | United States | $0.016B | 0.00 |
| Autonomix Medical (AMIX) | United States | $0.015B | 0.00 |
| QT Imaging Holdings (QTI) | United States | $0.012B | 0.00 |
| Aspira Women's Health (AWH) | United States | $0.011B | 0.00 |
| PAVmed (PAVM) | United States | $0.011B | 0.00 |
| T2 Biosystems (TTOO) | United States | $0.010B | 0.00 |
| Check-Cap (CHEK) | Israel | $0.004B | 0.00 |
| ReShape Lifesciences (RSLS) | United States | $0.004B | 0.00 |
| Nuwellis (NUWE) | United States | $0.003B | 0.00 |
| Avinger (AVGR) | United States | $0.002B | 0.00 |
| SINTX TECHNOLOGIES, INC (SINT) | United States | $0.002B | 0.00 |
| Nanovibronix (NAOV) | United States | $0.002B | 0.00 |
| ENDRA Life Sciences (NDRA) | United States | $0.002B | 0.00 |
| Venus Concept (VERO) | Canada | $0.002B | 0.00 |
| Bluejay Diagnostics (BJDX) | United States | $0.002B | 0.00 |
| Helius Medical Technologies (HSDT) | United States | $0.002B | 0.00 |
| Tenon Medical (TNON) | United States | $0.001B | 0.00 |
| Longview Acquisition II (LGV) | United States | $0.000B | 0.00 |
| Spinal Elements Holdings (SPEL) | United States | $0.000B | 0.00 |